MedTrace Logo

Risk Prediction of Taxane Chemotherapy-Induced Peripheral Neuropathy

NCT04932031 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 123

Last updated 2023-11-03

No results posted yet for this study

Summary

This is an observational study to discover risk factors of chemotherapy-induced peripheral neuropathy (CIPN) in 350 patients with early stage breast cancer undergoing taxane-based chemotherapy at two main sites (University of North Carolina at Chapel Hill (UNC) Hospital, including Rex Hospital, and the University of Alabama at Birmingham (UAB) Hospital). The primary purpose of this study to explore patient- and procedure-based variables that identify patients at risk for developing CIPN during chemotherapy.

Conditions

Sponsors & Collaborators

  • National Institute on Aging (NIA)

    collaborator NIH

  • University of North Carolina

    collaborator OTHER

  • University of Alabama at Birmingham

    collaborator OTHER

  • Sapere Bio

    lead INDUSTRY

Principal Investigators

  • Natalia Mitin, PhD · Sapere Bio

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-25
Primary Completion
2023-11-01
Completion
2023-11-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04932031 on ClinicalTrials.gov